目的 探究貝伐珠單抗注射液聯(lián)合甲磺酸阿美替尼片治療表皮生長因子受體（EGFR）突變型Ⅳ期非小細胞肺癌的臨床療效。方法 選取2021年1月—2023年1月臨汾市中心醫(yī)院收治的94例EGFR突變型Ⅳ期非小細胞肺癌患者作為研究對象，按隨機數(shù)字表法將所有患者分為對照組和治療組，每組各47例。對照組患者口服甲磺酸阿美替尼片，110 mg/次，1次/d。治療組在對照組基礎(chǔ)上靜脈滴注貝伐珠單抗注射液，15 mg/kg，每3周輸注1次。兩組均持續(xù)治療12周。比較兩組的臨床療效、生活質(zhì)量和血清因子水平。結(jié)果 治療后，治療組的疾病控制率為82.98%，高于對照組的59.57%，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組卡氏評分表（KPS）評分、生活質(zhì)量量表（SF-36）評分較治療前均顯著升高，血清正五聚蛋白3（PTX3）、趨化因子配體20（CCL20）水平較治療前均顯著降低（P＜0.05），且治療組生活質(zhì)量評分、血清因子水平較對照組更優(yōu)（P＜0.05）。結(jié)論 貝伐珠單抗注射液聯(lián)合甲磺酸阿美替尼片治療EGFR突變型Ⅳ期非小細胞肺癌可有效提高疾病控制效果，顯著改善患者生活質(zhì)量，調(diào)節(jié)血清中PTX3、CCL20水平。

Objective To investigate the effect of Bevacizumab Injection combined with Almonertinib Mesilate Tablets in treatment of EGFR mutant stage IV non-small cell lung cancer. Methods Patients (94 cases) with EGFR mutant stage IV non-small cell lung cancer in Linfen Central Hospital from January 2021 to January 2023 were divided into control and treatment groups according to the random number table method, and each group had 47 cases. Patients in the control group were po administered with Almonertinib Mesilate Tablets, 110 mg/time, once daily. Patients in the treatment group were iv administered with Bevacizumab Injection on the basis of the control group, 15 mg/kg, infusion once every 3 weeks. Patients in two groups were treated for 12 weeks. The clinical efficacies, quality of life, and serum factor levels in two groups were compared. Results After treatment, the disease control rate of the treatment group was 82.98%, higher than 59.57% of the control group, with a statistically significant difference (P < 0.05). After treatment, KPS scores and SF-36 scores of two groups were significantly increased, while serum levels of PTX3 and CCL20 in two groups were significantly decreased (P < 0.05). And KPS score and SF-36 score of the treatment group were higher, but the serum levels of PTX3 and CCL20 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Bevacizumab Injection combined with Almonertinib Mesilate Tablets in treatment of EGFR mutant stage IV non-small cell lung cancer can effectively improve the disease control effect, significantly improve quality of life, and regulate serum levels of PTX3 and CCL20.

R979.1

中華國際科學交流基金會檢驗檢測科技專項基金（Z2020LSXB004）